Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters
- 1 October 2002
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (20), 3009-3013
- https://doi.org/10.1016/s0960-894x(02)00615-7
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The next generation of PDE4 inhibitorsCurrent Opinion in Chemical Biology, 2001
- Genomic organization of the human phosphodiesterase PDE11A geneEuropean Journal of Biochemistry, 2001
- Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitorsImmunopharmacology, 2000
- Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functionsCurrent Opinion in Cell Biology, 2000
- New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung diseaseCurrent Opinion in Pulmonary Medicine, 2000
- House Dust Mite–induced Airway Changes in hu-SCID MiceAmerican Journal of Respiratory and Critical Care Medicine, 2000
- ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to ClinicPulmonary Pharmacology & Therapeutics, 1999
- Phosphodiesterase IsozymesAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic DermatitisJournal of Investigative Dermatology, 1996
- Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan‐stimulated respiratory burst by ‘type IV’‐selective PDE inhibitorsBritish Journal of Pharmacology, 1991